Interferon alpha kinoid

Drug Profile

Interferon alpha kinoid

Alternative Names: Antiferon; IFN-K - Neovacs; IFNα kinoid

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neovacs
  • Developer Department Immunology of Diabetes at Hospital Cochin; Neovacs; sanofi pasteur
  • Class Interferons; Vaccines
  • Mechanism of Action Immunomodulators; Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dermatomyositis; Systemic lupus erythematosus
  • Preclinical Type 1 diabetes mellitus
  • Discontinued HIV infections; Sjogren's syndrome

Most Recent Events

  • 19 Jul 2017 Phase-II clinical trials in Dermatomyositis in Italy, France (IM)
  • 19 Jul 2017 US FDA approves IND application for Interferon alpha kinoid in Dermatomyositis
  • 11 Jul 2017 NeoVacs receives third positive opinion from the Independent Data and Safety Monitoring Board for phase IIb trial in Systemic lupus erythematosus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top